<PAGE>   1


                                   FORM 10-Q

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON D.C. 20549

(MARK ONE)

/X/         QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE
                        SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 1995
                                       OR

/ /         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                        SECURITIES EXCHANGE ACT OF 1934

For the transition period from                   to
                               -----------------    -----------------
Commission file number 1-7081

                             CUSTOMEDIX CORPORATION
              (Exact name of registrants specified in its charter)


            Delaware                                     #22-1844840
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)

     P. O. BOX 724, 53 NORTH PLAINS INDUSTRIAL ROAD, WALLINGFORD, CT 06492
                    (Address of principal executive offices)
                                   (Zip Code)

                                  203-284-9079
              (Registrant's telephone number, including area code)

  ---------------------------------------------------------------------------
  (Former name, former address and former fiscal year, if changed since last
                                    report)

         Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15 (d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

  Yes X     No
     ---      ---
         Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the close of the period covered by this report.

           Class                             Outstanding at September 30, 1995
Common stock $.01 par value                              3,295,986


<PAGE>   2

Item 1.                              PART I
                            CUSTOMEDIX  CORPORATION
                    CONDENSED  CONSOLIDATED  BALANCE  SHEETS
================================================================================
<TABLE>
<CAPTION>
                                                                September 30,           June 30,
                                                                     1995                 1995
                                                                 (Unaudited)               (a)
                                                                -------------           --------
<S>                                                             <C>                 <C>
                                     ASSETS
                                     ------

CURRENT ASSETS:
  Cash and cash equivalents                                     $    294,009        $    166,670
  Accounts receivable, less allowance
   for possible losses of $301,900 and $283,000                    6,433,276           6,862,206
  Inventory  (Note 3)                                              7,917,516           7,411,332
  Other                                                              582,700             581,698
                                                                ------------        ------------

                   TOTAL CURRENT ASSETS                           15,227,501          15,021,906

PROPERTY AND EQUIPMENT, less accumulated
  depreciation and amortization of $3,870,379
  and $3,714,656 (Note 6)                                          3,156,172           3,148,573

EXCESS OF COST OVER NET ASSETS OF BUSINESSES
  ACQUIRED, less accumulated amortization of
  $2,402,600 and $2,331,371                                        4,738,435           4,809,664



OTHER ASSETS                                                         409,791             416,159
                                                                ------------        ------------

                   TOTAL ASSETS                                 $ 23,531,899        $ 23,396,302
                                                                ============        ============

                      LIABILITIES AND STOCKHOLDERS' EQUITY
                      ------------------------------------

CURRENT LIABILITIES:
  Current portion of long-term debt and
    obligations under capital leases (Note 5)                   $    978,918        $  1,050,600
  Accounts payable and accrued expenses                            3,556,886           3,330,687
                                                                ------------        ------------

                   TOTAL CURRENT LIABILITIES                       4,535,804           4,381,287

LONG-TERM DEBT AND OBLIGATIONS UNDER CAPITAL
  LEASES, less current portion (Note 5)                            6,675,818           6,823,926
LONG-TERM PENSION OBLIGATION AND OTHER                             1,894,100           1,788,894
                                                                ------------        ------------
                   TOTAL LIABILITIES                              13,105,722          12,994,107
                                                                ------------        ------------

STOCKHOLDERS' EQUITY:
  Preferred stock, $1.00 par value - 100,000
    shares authorized; none issued                                        --                  --
  Common stock, $.01 par - 3,900,000 shares
    authorized; outstanding 3,295,986 and 3,296,286                   32,960              32,963
  Additional paid-in capital                                      26,833,581          26,834,399
  Accumulated deficit                                            (16,440,364)        (16,465,167)
                                                                ------------        ------------

                   TOTAL STOCKHOLDERS' EQUITY                     10,426,177          10,402,195
                                                                ------------        ------------

                   TOTAL LIABILITIES AND STOCKHOLDERS'
                       EQUITY                                   $ 23,531,899        $ 23,396,302
                                                                ============        ============
</TABLE>

(a)  Derived from the audited financial statements
See accompanying "Notes to Condensed Consolidated Financial Statements".


                                       2
<PAGE>   3

                             CUSTOMEDIX CORPORATION
                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                  (UNAUDITED)
================================================================================
<TABLE>
<CAPTION>
                                                           Three Months Ended
                                                             September 30,
                                                    -------------------------------
                                                         1995               1994
                                                         ----               ----
<S>                                                  <C>                <C>
REVENUES:

    Sales                                            $11,977,499        $11,384,289
    Other income                                         122,059            111,923
                                                     -----------        -----------

                 Total revenues                       12,099,558         11,496,212
                                                     -----------        -----------

COSTS, EXPENSES AND OTHER:
    Cost of sales                                      8,721,851          8,328,231
    Selling, general and administrative
      expenses                                         3,104,595          2,806,893
    Interest expense - net of interest
      income of $25 and $0                               228,309            223,678
                                                     -----------        -----------
                                                      12,054,755         11,358,802
                                                     -----------        -----------


      Income before provision for income taxes            44,803            137,410

PROVISION FOR INCOME TAXES (Note 4)                      (20,000)           (60,000)
                                                     -----------        -----------

NET INCOME                                           $    24,803        $    77,410
                                                     ===========        ===========

INCOME PER SHARE  (Note 2)                           $       .01        $       .02
                                                     ===========        ===========

</TABLE>

See accompanying "Notes to Condensed Consolidated Financial Statements".





                                       3
<PAGE>   4
                             CUSTOMEDIX CORPORATION
                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                  (UNAUDITED)
================================================================================
<TABLE>
<CAPTION>
                                                             Three Months Ended
                                                               September 30,
                                                         --------------------------
                                                            1995             1994
                                                            ----             ----
<S>                                                      <C>              <C>
Cash flows from operating activities:                    $  24,803        $  77,410
  Net income

 Adjustments to reconcile net income to net cash
     provided by operating activities:
       Depreciation                                        155,723          149,000
       Amortization                                         79,212          108,617
       Loss on disposal of property and equipment             --                788
       Provision for loss on accounts receivable            39,747           27,999
       Change in assets and liabilities:
             Accounts receivable                           389,183          646,935
             Inventory                                    (506,184)        (489,795)
             Other assets                                   (2,617)         699,353
             Accounts payable and accrued expenses         226,199         (859,113)
             Other liabilities                             105,206           96,944
                                                         ---------        ---------

         Net cash provided by operating
             activities                                    511,272          458,138
                                                         ---------        ---------

Cash flows from investing activities:
         Purchase of property and equipment               (163,318)        (127,591)
                                                         ---------        ---------


Cash flows from financing activities:
         Repayments to banks and others                   (219,790)        (320,016)
         Repurchase and retirement of common stock            (825)            --
                                                         ---------        ---------

         Net cash used in financing activities            (220,615)        (320,016)
                                                         ---------        ---------

         Net increase in cash and
             cash equivalents                              127,339           10,531


Cash and cash equivalents, beginning
    of period                                              166,670          477,983
                                                         ---------        ---------

Cash and cash equivalents, end of period                 $ 294,009        $ 488,514
                                                         =========        =========

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
    Cash paid during the period for -
         Interest                                        $ 227,907        $ 274,300
         Income taxes                                      124,725           81,300

</TABLE>

See accompanying "Notes to Condensed Consolidated Financial Statements".


                                       4
<PAGE>   5

                             CUSTOMEDIX CORPORATION
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               SEPTEMBER 30, 1995
                                  (UNAUDITED)
================================================================================

Note 1 - Basis of Presentation

         The accompanying unaudited, condensed consolidated financial statements
         have been prepared by the Company in accordance with generally accepted
         accounting principles for interim financial information, and pursuant
         to the rules and regulations of the Securities and Exchange Commission.
         Certain information and footnote disclosures normally included in the
         financial statements have been condensed or omitted pursuant to such
         rules and regulations, although management believes that the
         disclosures are adequate to make the information presented not
         misleading. In the opinion of management, the accompanying condensed
         consolidated financial statements contain all adjustments (consisting
         of only normal recurring accruals) necessary for a fair presentation of
         the results for the interim periods presented. The results for the
         interim periods are not necessarily indicative of the results to be
         expected for the full year.  It is suggested that these condensed
         consolidated financial statements be read in conjunction with the
         financial statements and the notes thereto included in the Company's
         Annual Report to Stockholders.


Note 2 - Earnings Per Share

         Income per share was computed based on the weighted average number of
         common stock and common stock equivalent shares outstanding during each
         period.  There were 3,318,100 and 3,698,200 weighted average shares
         outstanding for the three months ended September 30, 1995 and 1994,
         respectively.

Note 3 - Inventory

         Inventory is summarized as follows:


<TABLE>
<CAPTION>
                                           September 30, 1995        June 30,1995
                                           ------------------        ------------
         <S>                               <C>                       <C>
         Finished Products                     $5,080,696             $4,592,441
         Work-In-Process                          810,397                694,073
         Raw Material & Supplies                2,026,423              2,124,818
                                                ---------              ---------

         Total                                 $7,917,516             $7,411,332
                                               ==========             ==========
</TABLE>


Note 4 - Income Taxes

         The provision for income taxes represents minimum federal and state
         income taxes. The Company has recognized a deferred tax asset to the
         extent existing deductible temporary differences are expected to
         reverse and enable the Company to recapture alternative minimum taxes
         previously paid.  The deferred tax assets totalling $205,000 and
         $170,000 in fiscal 1996 and 1995, respectively, are included in other
         current assets.





                                       5
<PAGE>   6

                             CUSTOMEDIX CORPORATION
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                               September 30, 1995
                                  (UNAUDITED)
================================================================================

Note 5 - Long-Term Debt and Obligations Under Capital Leases

         Long-term debt and obligations under capital leases are summarized as
         follows:

<TABLE>
<CAPTION>
                                           September 30, 1995     June 30, 1995
                                           ------------------     -------------
         <S>                                   <C>                <C>      
         Term Loan                             $6,116,336          $6,279,002
         Revolving credit facility                300,000             300,000
         Obligations under capital
          leases                                  597,595             656,292
         Note payable to officer                  591,500             591,500
         Other                                     49,305              47,732
                                               ----------          ----------
                                                7,654,736           7,874,526

         Less current portion                     978,918           1,050,600
                                               ----------          ----------

             Total                             $6,675,818          $6,823,926
                                               ==========          ==========
</TABLE>

Note 6 - Property and Equipment

         Major classes of property and equipment consist of the following:

<TABLE>
<CAPTION>
                                           September 30, 1995     June 30, 1995
                                           ------------------     -------------
         <S>                               <C>                    <C>
         Machinery and equipment               $3,452,777          $3,411,694
         Leasehold improvements                 2,131,022           2,081,034
         Furniture and fixtures                 1,410,211           1,337,960
         Transportation equipment                  32,541              32,541
                                               ----------          ----------
                     Total                      7,026,551           6,863,229

         Less accumulated depreciation
           and amortization                     3,870,379           3,714,656
                                               ----------          ----------

                                               $3,156,172          $3,148,573
                                               ==========          ==========
</TABLE>

Note 7 - Reclassifications

         Certain reclassifications have been made to the fiscal 1995
         consolidated financial statements in order for them to be presented in
         conformity with the fiscal 1996 consolidated financial statements.


                                       6
<PAGE>   7
Item 2.
                             CUSTOMEDIX CORPORATION
               MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                      CONDITION AND RESULTS OF OPERATIONS

================================================================================


Three Months Ended September 30, 1995 vs. September 30, 1994

Operations

         Sales for the quarter ended September 30, 1995 were $11,977,500
compared to $11,384,300 for the quarter ended September 30, 1994, an increase
of $593,200 or 5.2%.  This increase was primarily attributable to higher sales,
both domestic and foreign, of most of the Company's dental products, offset by
a $129,000 decrease in medical sales by the Company's subsidiary, Transidyne
General Corporation ("Transidyne").

         Gross profit as a percentage of sales was 27.2% for the quarter ended
September 30, 1995 compared to 26.8% for the quarter ended September 30, 1994.
Gross profit as a percentage of sales was 26.5% for fiscal year ended June 30,
1995.

         Selling, general and administrative expenses were $3,104,600 for the
quarter ended September 30, 1995 compared to $2,806,900 for the same quarter
last year.  This increase of $297,700 was primarily attributable to increases
in advertising expenses, professional fees, research and development and
salaries as well as expenses associated with an alleged employee
misappropriation of funds at Transidyne.

         Interest expense for the quarter ended September 30, 1995 was $228,300
compared to $223,700 for the quarter ended September 30, 1994. This increase
was attributable to increases in interest rates and was partially offset by a
reduction in long-term debt.

         Income before income taxes was $44,800 for the quarter ended September
30, 1995 compared to $137,400 for the quarter ended September 30, 1994.  This
decrease of $92,600 was primarily attributable to increased selling, general
and administrative expenses and was offset in part by increased gross profit
due to increased sales.

Impact of Inflation

         The Company experienced only minor inflation-related cost increases
which were not a material factor in the comparison of expenses with respect to
the periods compared.


                                       7

<PAGE>   8

                             CUSTOMEDIX CORPORATION
               MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                      CONDITION AND RESULTS OF OPERATIONS

================================================================================



Liquidity and Capital Resources

         Working capital increased by approximately $51,100 to $10,691,700 at
September 30, 1995 as compared to $10,640,600 at June 30, 1995.  This increase
was due primarily to earnings of the Company during the period.

         For the three months ended September 30, 1995, cash generated by
operations and cash on hand were primarily used as follows:  (i) to reduce debt
by approximately $219,800 and (ii) to purchase property and equipment totaling
approximately $163,300.

         As of September 30, 1995, the Company was in compliance with all of
the financial convenants contained in the loan agreement, as amended, with the
Company's principal lending bank (the "Bank"). The Company and the Bank have
agreed to an amendment to the agreement which would extend the maturity on the
term loan until January 2, 2000 from January 2, 1997.  Also, the Revolving Line
of Credit would be increased from $600,000 to $1,000,000 and would be payable
on demand.  The interest rate on the term loan and the Revolving Line of Credit
would be reduced from 1/4% above the Bank's index rate to the Bank's index
rate.

         The Company expects significant demands on cash during the next twelve
months as a result of anticipated advertising expenses, salaries, professional
fees,and federal alternative minimum taxes and state income taxes. In addition,
because of the Company's substantial debt burden, a significant portion of cash
flow will continue to be used to repay debt.  This substantial use of cash
limits the funds available for general working capital purposes, product
research and marketing, as well as funds that can be expended on new facilities
and capital equipment. Furthermore, the ability of the Company to expand
operations through mergers or acquisitions is limited by the lack of available
cash with which to fund such activities.


Future Outlook

         The Company expects to continue to incur high expenses in the areas of
new product development and research and product introduction.  The Company
expects these efforts will primarily focus on dental products, and the
associated expenses could contribute to reduced earnings.  In addition, the
dental products market faces increasing competition and profitability
pressures, both in domestic and foreign markets.  Accordingly, the Company may
experience further reduction in its margins on certain dental products.  The
Company is highly leveraged and any significant increase in interest rates
could materially and adversely affect the Company's profitability and cash
flow.



                                       8

<PAGE>   9
                                    PART II
                             CUSTOMEDIX CORPORATION
                               OTHER INFORMATION

================================================================================


Item 1.     Legal Proceedings

            There has been no material change from the information set forth in
Item 3 of the Company's Annual Report on Form 10-K for the fiscal year ended
June 30, 1995 except as follows:

            The Company's subsidiary, Jeneric/Pentron, Inc., has recently filed
suit in Connecticut Superior Court against two former employees and business
entities with which they are affiliated for unfair trade practices and breach of
common law duties of loyalty in connection with the alleged sales of dental
products through companies in competition with Jeneric/Pentron, Inc. The Company
is seeking injunctive relief and damages.

Item 6.     Exhibits and Reports on Form 8-K

            (a)   Exhibits:  

                  27  Financial Data Schedule

            (b)   Reports on Form 8-K:  None





                                       9
<PAGE>   10

                                   SIGNATURES




     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.





November 14, 1995                                   Customedix Corporation
Date                                                -----------------------
                                                    Registrant





                                                    /s/ Gordon S. Cohen
                                                    -----------------------
                                                    Gordon S. Cohen
                                                    Chairman and
                                                    Chief Executive Officer





                                                    /s/ Barry L. Kosowsky
                                                    ----------------------------
                                                    Barry L. Kosowsky
                                                    Principal Financial Officer
                                                    Principal Accounting Officer



                                       10